Comparative Pharmacology
Head-to-head clinical analysis: ACETADOTE versus FUSILEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETADOTE versus FUSILEV.
ACETADOTE vs FUSILEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetylcysteine serves as a precursor to glutathione, replenishing hepatic glutathione stores and enhancing the detoxification of the toxic metabolite N-acetyl-p-benzoquinoneimine (NAPQI) in acetaminophen overdose.
FUSILEV (levoleucovorin) is the pharmacologically active isomer of folinic acid. It bypasses dihydrofolate reductase inhibition by dihydrofolate reductase inhibitors (e.g., methotrexate), providing reduced folate that is used in DNA synthesis and repair. It also enhances the efficacy of fluorouracil by stabilizing the ternary complex of thymidylate synthase, thereby inhibiting DNA synthesis.
Intravenous loading dose of 150 mg/kg over 60 minutes, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours (total 300 mg/kg over 21 hours). Oral: 140 mg/kg loading dose, then 70 mg/kg every 4 hours for 17 doses.
Leucovorin (Fusilev) 200 mg/m2 IV over 2 hours, followed by 5-fluorouracil bolus and infusion, repeated every 2 weeks in combination regimens for advanced colorectal cancer.
None Documented
None Documented
Terminal elimination half-life: 5.6 hours (range 4.1-7.6). In acetaminophen overdose, half-life may be prolonged (up to 20 hours) due to saturation of metabolic pathways.
The terminal elimination half-life of the active metabolite, 5-methyltetrahydrofolate (5-MTHF), is approximately 6-8 hours in healthy adults; clinically, this supports twice-daily or daily dosing schedules.
Renal: 60-80% as unchanged drug and metabolites (sulfate, glucuronide, cysteine, N-acetylcysteine conjugates). Fecal: minor (less than 3%).
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 40-60% of the dose; fecal excretion is negligible.
Category C
Category C
Antidote
Antidote